Engineering Biology at the Nanoscale (RMI)

纳米级工程生物学 (RMI)

• 批准号: 6931323
• 负责人: DAVID NEEDHAM
• 金额: $ 6.38万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-09-30 至 2005-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6931323
• 关键词: molecular biology; nanotechnology

The broad vision of the COM is to create a new paradigm for engineering Biology, especially at the molecule, membrane and cellular level. The Center's main focus will be to explore how and to what extent we can more formally map traditional engineering principles, especially component design and materials selection, onto Biology at nanoscales reverse engineering biology's products and processes; and to then forward engineering new products and processes that lead to improved treatments in health and disease. In the CDP we will bring together teams of world-class investigators at Duke, each led by team leaders, to evaluate the Nanomedicine components in four initial focus areas: Drug Delivery and Molecular Design, In Vivo Force Measurements, the Role of Inflammation in Heart Disease and Cancer, and Orthopedic Bioengineering, exploring our engineering mapping concepts onto each biological system and medical application. We have already established micro and nano probe techniques to measure important properties and performance of various molecules, membranes and cells. Taking these approaches to the next level of complexity, and using our nanoscale measurements to explore biology in vivo for particular diseased states, is the overall goal of our Nanomedicine Development Center. In our CDP workshops and discussions, we will show: 1) how we will use our mapping approaches to identify areas of expertise and expert personnel, and, importantly, areas that we do not cover, generating possible potential areas for collaboration; 2) test them against our definition of nano medicine, thereby making a list of potential areas, themes and technologies that we might offer to the CDP network; and 3) develop a full proposal that focuses on our final choice of expert themes, technologies, and disease states, creating a new body of knowledge and know-how. A particular contribution will be to offer a dedicated resource of mapping methodology that can interact with and complement the other two or three centers in this initiative.

COM的广泛视野是为工程生物学创建一个新的范式，尤其是在分子，膜和细胞水平上。该中心的主要重点将是探索如何以及在何种程度上可以正式地将传统工程原理（尤其是组件设计和材料选择）映射到纳米级反向工程生物学的产品和过程的生物学上；然后将新产品和过程转发，从而改善了健康和疾病的治疗方法。在CDP中，我们将召集杜克大学的世界一流调查员团队，每个团队负责人都在四个初始重点领域中评估纳米医学成分：药物输送和分子设计，体内力量测量，炎症在心脏病和癌症中的作用，以及骨科医学的作用 生物工程，将我们的工程映射概念探索到每个生物系统和医疗应用上。我们已经建立了微观和纳米探针技术，以测量各种分子，膜和细胞的重要特性和性能。将这些方法采用了新的复杂性，并使用我们的纳米级测量值来探索特定患病状态的体内生物学，这是我们纳米医学开发中心的总体目标。在我们的CDP研讨会和讨论中，我们将展示：1）我们将如何使用映射方法来识别专业知识和专家人员的领域，重要的是，我们不涵盖的领域，为协作带来了可能的潜在领域； 2）测试它们反对我们对纳米医学的定义，从而列出了我们可能向CDP网络提供的潜在领域，主题和技术的清单； 3）制定一个完整的建议，重点是我们最终的专家主题，技术和疾病状态，创造了一个新的身体 知识和知识。一个特定的贡献将是提供映射方法的专用资源，该方法可以与该计划中的其他两个或三个中心进行交互并补充。